Taggart A J, Astbury C, Dixon J S, Bird H A
Clin Rheumatol. 1986 Sep;5(3):327-31. doi: 10.1007/BF02054250.
The pharmacokinetic profile of a single 10 mg oral dose of prednisolone was studied in three groups of six patients with rheumatoid arthritis (RA), polymyalgia rheumatica (PMR) and bronchial asthma (BA) who were already receiving steroid therapy. A fourth group of age and sex-matched normal controls was also studied. Kinetic parameters (including elimination half-life, area under the plasma concentration curve, apparent volume of distribution and total body clearance) were similar for all four groups but there was considerable inter-subject variability. The correlations between these kinetic parameters and age, body weight and serum albumin were poor. The results suggest that any differences in the effects of corticosteroids in these inflammatory diseases are unlikely to be due to pharmacokinetic factors. The duration of steroid therapy and the reduction in patient mobility would appear to be more likely explanations for the reduction in bone mass observed in patients with RA.
对三组各六名已接受类固醇治疗的类风湿性关节炎(RA)、风湿性多肌痛(PMR)和支气管哮喘(BA)患者,研究了口服10毫克单剂量泼尼松龙的药代动力学特征。还研究了第四组年龄和性别匹配的正常对照者。所有四组的动力学参数(包括消除半衰期、血浆浓度曲线下面积、表观分布容积和全身清除率)相似,但个体间存在相当大的变异性。这些动力学参数与年龄、体重和血清白蛋白之间的相关性较差。结果表明,皮质类固醇在这些炎症性疾病中作用的任何差异不太可能归因于药代动力学因素。类固醇治疗的持续时间和患者活动能力的下降似乎更有可能解释RA患者中观察到的骨量减少。